Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | ACR | P10323 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133955 | 1.00 | KMT2A (0.53) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL13637985 | 0.85 | KMT2A (0.54) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| Sumacetamol SCHEMBL5185790 | 0.83 | GAA (0.55) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| Sumacetamol SCHEMBL1134071 | 0.83 | GAA (0.55) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL13637924 | 0.83 | KMT2A (0.51) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133856 | 0.82 | KMT2A (0.57) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL12229268 | 0.82 | LMNA (0.43) | KMT2AMEN1LMNACYP1A2GAA | |
| SCHEMBL12229225 | 0.82 | LMNA (0.43) | KMT2AMEN1LMNACYP1A2GAA | |
| SCHEMBL426545 | 0.81 | KMT2A (0.58) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 | |
| SCHEMBL1133966 | 0.81 | KMT2A (0.58) | KMT2AMEN1HSD17B10SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951001-B2 | Hepatoprotectant acetaminophen mutual prodrugs | ACORDA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951001-B2 | Hepatoprotectant acetaminophen mutual prodrugs | ACORDA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. | 2016-11-10 | — | — | US | disclosed |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | ACORDA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | ACORDA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| CN-102149412-A | Hepatoprotectant acetaminophen mutual prodrugs | NEUROGESX INC | 2011-08-10 | — | — | CN | disclosed |
| EP-2285419-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | Neurogesx, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143299-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326107-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | KMT2A 4597/4885MEN1 4430/4885HSD17B10 463/4885 |
| US-20110263545-A1 | HEPATOPROTECTANT ACETAMINOPHEN MUTUAL PRODRUGS | PTGS1, HPGD, PYGL | KMT2A 4597/4885MEN1 4430/4885HSD17B10 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.